Immunogen (IMGN) Reports First Patient Dosed in Phase 1 Study of IMGN632 for Hematological Malignancies
Tweet Send to a Friend
ImmunoGen, Inc. (NASDAQ: IMGN) today announced that the first patient has been treated with IMGN632 in a Phase 1 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
